ALS Invest 1 B.V. 3
3 · Amylyx Pharmaceuticals, Inc. · Filed May 5, 2022
Insider Transaction Report
Form 3
ALS Invest 1 B.V.
10% Owner
Holdings
Series A Preferred Stock
→ Common Stock (1,129,386 underlying)Series B Preferred Stock
→ Common Stock (4,826,503 underlying)
Footnotes (2)
- [F1]Each share of Series A and Series B preferred stock (collectively the "Preferred Stock") is convertible on a one-for-one basis into Common Stock at any time at the election of the Reporting Person and will automatically convert upon the closing of the Issuer's initial public offering into the number of shares of the Issuer's Common Stock shown in column 3 without payment or further consideration. The Preferred Stock has no expiration date.
- [F2]The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person.